Lentiviral gene therapy for X-linked chronic granulomatous disease recapitulates endogenous CYBB regulation and expression
Blood · 2023
DOI: 10.1182/blood.2022016074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Ryan L Wong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA. Hauptthemen laut MEDLINE: Granulomatous Disease, Chronic. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
X-linked chronic granulomatous disease (X-CGD) is a primary immunodeficiency caused by mutations in the CYBB gene, resulting in the inability of phagocytic cells to eliminate infections. To design a lentiviral vector (LV) capable of recapitulating the endogenous regulation and expression of CYBB, a bioinformatics-guided approach was used to elucidate the cognate enhancer elements regulating the native CYBB gene. Using this approach, we analyzed a 600-kilobase topologically associated domain of the CYBB gene and identified endogenous enhancer elements to supplement the CYBB promoter to develop MyeloVec, a physiologically regulated LV for the treatment of X-CGD. When compared with an LV currently in clinical trials for X-CGD, MyeloVec showed improved expression, superior gene transfer to hematopoietic stem and progenitor cells (HSPCs), corrected an X-CGD mouse model leading to complete protection against Burkholderia cepacia infection, and restored healthy donor levels of antimicrobial oxidase activity in neutrophils derived from HSPCs from patients with X-CGD. Our findings validate the bioinformatics-guided design approach and have yielded a novel LV with clinical promise for the treatment of X-CGD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
- ImmunoVec, Los Angeles, CA.
- Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
- Department of Ophthalmology, Duke University Eye Center, Durham, NC.
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
- Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
ORCID-Profile: Ryan L Wong, Sarah Sackey, Jason P Quintos, Luke Riggan, Harry L Malech, Donald B Kohn
Förderung
- NIAID NIH HHS
Zitieren
APA
Wong, R. L., Sackey, S., Brown, D., Senadheera, S., Masiuk, K., Quintos, J. P., Colindres, N., Riggan, L., Morgan, R. A., Malech, H. L., Hollis, R. P., & Kohn, D. B. (2023). Lentiviral gene therapy for X-linked chronic granulomatous disease recapitulates endogenous CYBB regulation and expression. Blood. https://doi.org/10.1182/blood.2022016074
Vancouver
Wong RL, Sackey S, Brown D, Senadheera S, Masiuk K, Quintos JP, et al. Lentiviral gene therapy for X-linked chronic granulomatous disease recapitulates endogenous CYBB regulation and expression. Blood. 2023. doi:10.1182/blood.2022016074
BibTeX
@article{Wong2023,
author = {Wong, Ryan L and Sackey, Sarah and Brown, Devin and Senadheera, Shantha and Masiuk, Katelyn and Quintos, Jason P and Colindres, Nicole and Riggan, Luke and Morgan, Richard A and Malech, Harry L and Hollis, Roger P and Kohn, Donald B},
title = {Lentiviral gene therapy for X-linked chronic granulomatous disease recapitulates endogenous CYBB regulation and expression},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022016074}
}
EUVIMED